Background. Strict control of serum calcium and phosphate concentrations is paramount to prevent secondary hyperparathyroidism in haemodialysis (HD) patients. Standard intermittent low-flux HD (Lf-HD) is not sufficient to reach this goal. The aim of this study was to evaluate the effect of on-line haemodiafiltration (Ol-HDF) on serum calcium (sCa), phosphate (sPO4) and parathyroid hormone (PTHint) concentrations. Methods. Of the 220 patients screened, 65 met the inclusion criteria for the study; 30 of whom agreed to participate in the study (Study group), the others were considered as the control group (Controls). Protocol for Study the group consisted of 6 months conventional Lf-HD (Period 1) and 6 months of post-dilutional Ol-HDF (Period 2). Controls continued their usual Lf-HD and were followed for 12 months. The main variables evaluated at the start and at the end of each period were sCa, sPO 4 and PTHint. Results. The switchover from Lf-HD to Ol-HDF resulted in a significant reduction of sPO4 (from 5.1 6 1.0 to 4.0 6 0.7; P < 0.0001) and PTHint concentrations (from 307 6 167 to 194 6 98; P < 0.0001), no significant changes were found in both sCa concentrations (from 9.1 6 0.7 to 8.9 6 0.6) and phosphate binder dose. Kt/Vurea increased significantly, and beta 2 microglobulin concentrations decreased significantly. In the Controls, no significant variations of the same variables were observed over time, except for a significant increase in sevelamer intake. Conclusion. This study supports the idea that Ol-HDF could be better than Lf-HD in controlling mineral metabolism in HD patients.
Introduction
Strict control of serum calcium and phosphate levels is of paramount importance to prevent parathyroid hormone (PTHint) stimulation and renal osteodystrophy in chronic haemodialysis (HD) patients [1] . Moreover, it is now well recognized that high serum phosphate levels are an independent predictor of mortality in dialysis patients [2] [3] [4] probably by promoting the development of either peripheral or coronary vascular calcifications [5, 6] . However, treatment of hyperphosphataemia in HD patients continues to be a challenge, since almost 50% of HD patients have serum phosphate levels greater than the recommended treatment targets in spite of the use of phosphate binders and dietary advice [2] .
Recently, several studies have shown that increasing the frequency of dialysis with short daily HD and/or increasing treatment time with nocturnal haemodialysis results in lower phosphate concentrations or decreased use of phosphate binders, while standard intermittent low-flux HD (Lf-HD) is not sufficient to reach this goal [7, 8] . The use of synthetic highflux membranes particularly in the on-line haemodiafiltration (Ol-HDF) modality, combining elevated diffusion and convection rates, could be more effective [9] . Short-term studies have shown that phosphate removal is increased during HDF [10, 11] ; however, it is not currently defined if this increased removal could result in better long-term control of pre-dialysis phosphate and mineral metabolism parameters. The aim of this study was to evaluate the effect of a switchover from standard Lf-HD to Ol-HDF on serum calcium (sCa), phosphate (sPO 4 ) and PTHint concentrations.
Materials and methods
We performed a prospective comparison of the effect of a switchover from standard low-flux HD (Lf-HD) to post-dilutional Ol-HDF on sCa, sPO 4 and PTHint concentrations in a cohort of prevalent HD patients followed at the Division of Nephrology, Spedali Civili and Section of Nephrology University of Brescia, at the Dialysis Centre of Gardone VT and at the Dialysis Centre of Gussago Brescia from 1 January 2005 to 31 December 2007. The study was conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from each participant.
Inclusion criteria
All prevalent patients on regular thrice weekly Lf-HD treatment for at least 6 months. Urinary output 150 mL/day before enrolment.
Exclusion criteria
Exclusion criteria were age <18 years, treatment with haemodiafiltration or high-flux HD in the 6 months before the beginning of the study, neoplasia (any), acute clinical conditions (myocardial infarction, congestive heart failure, stroke, recent surgery, or severe sepsis) within 3 months before study, presence of central venous catheters or vascular access dysfunction (blood flow rate < 300 mL/min).
Of the 220 patients screened for eligibility, 65 met the inclusion criteria. Of these 65 patients, 30 agreed to participate in the study protocol (Study group), the others did not agree and were considered as the control group (Controls).
Study design
The study protocol for patients in the Study group consisted in the 6 months conventional Lf-HD (Period 1) immediately followed by 6 months of post-dilutional Ol-HDF (Period 2). Controls continued their usual Lf-HD and were followed for the next 12 months.
During Lf-HD, blood flow rate (Q b ; median 300 mL/min; range 280-310 mL/min), dialysis time (Td median 240 min; range 210-270 min) and dialysate flow (Q d 500 mL/min) were kept constant during the study in both groups and periods. Post-dilutional Ol-HDF was performed using High-flux filters of the same surface and membrane type of Lf-HD (Fresenius FX8 and FX80 helixone membranes and Gambro Polyflux 17L, 21L and Polyflux170H, 210H), using Fresenius 5008 or Gambro AK 200 machines. Sixteen patients in the Study group and 18 Controls were on Helixone membranes and the others on Polyflux membranes.
In all patients, both Lf-HD and Ol-HDF were performed with ultrapure dialysis fluids containing <0.1 colony-forming units/mL and <0.03 endotoxin unit/mL [12] . Water purification was based on double reverse osmosis and the quality of dialysis solutions was monitored regularly according to the Italian Guidelines on water and solutions for dialysis [13] . The Ol-HDF fraction was set at 35% of the Q b, and the target Ol-HDF volume of exchange was 40% of the total body water according to the Watson's formula. Dialysate and replacement fluid ion composition was as follows: Na, 140 mmol/L; K, 2-3 mmol/L; Ca, 1.5 mmol/L; bicarbonate, 35 mmol/L; acetate, 4 mmol/L and glucose, 5.55 mmol/L and was not changed during the study.
The variables studied were evaluated both at the start and at the end of each period of observation. They included serum calcium (sCa; mg/dL), serum phosphorus (sPO 4 ; mg/dL), serum intact parathyroid hormone (PTHint; ng/mL), serum beta 2 microglobulin (b 2 M; mg/dL), total serum protein (sProt; g/dL), serum albumin (sAlb; g/dL), plasma sodium (Na; mmol/L), plasma potassium (K; mmol/L), equilibrated Kt/V (eKt/V), body weight (BW; kg), pre-dialysis systolic blood pressure (SBP; mmHg) and diastolic blood pressure (DBP; mmHg).
Treatment of mineral bone derangement was performed according to the American Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in chronic renal failure recommendations [14] . The phosphate treatment goal was defined as sPO 4 concentration 5.5 mg/dL which is the upper limit of the range defined by K/DOQI. In the Study group, prescription and dosage changes of the phosphate binders (calcium carbonate and/or sevelamer) were allowed during Period 1 and were kept constant during Period 2. In Controls, changes in the dosage and prescription of phosphate binders supplementation were always allowed according to the clinical judgment of the attending nephrologist. In order to reduce possible bias on the effective phosphate binders assumption, regular advice was given to the patients by the attending physician during the entire period of study, the only check system for compliance being the regular request for drug prescription by the patients. Fifteen patients out of 30 in the Study group and 18/35 Controls were on calcitriol treatment, none were on paricalcitol and cinacalcet treatment. No variation in vitamin D dosage was made during the period of study in both groups.
Determinations
Dry BW was clinically determined and reflects the lowest weight the patient could tolerate without intradialytic symptoms and hypotension in the absence of overt fluid overload and was modified by the attending physician as needed. Pre-dialysis SBP and DBP were the mean values for each patient during a 2-week period (six dialysis sessions). All biochemical parameters were drawn before dialysis after the long interdialysis period. sCa and sPO 4 were measured by bromocresol and phosphomolibdate colorimetric assay; PTHint and b 2 M by automated immunoassay and immunometric assay (Immunolite 2000; Siemens, Munich, Germany) and the other biochemical parameters by standard laboratory methods. eKt/V was obtained midweek and calculated according to Daugirdas [15] .
Statistical analysis
Continuous data were analysed descriptively as mean AE SD and 95% confidence intervals for the mean or median and range according to their distribution. Comparison among patients was performed using t-test for paired and unpaired data for normally distributed parameters, MannWhitney U-test for medians, v 2 test for proportions and linear regression analysis. Significant differences were defined as P <0.05. All statistical analyses were performed using Statgraphics Centurion for Windows software (StatGrgaphics CenturionÒ). Table 1 shows the main demographic and clinical characteristics of the 30 patients who underwent the switchover from Lf-HD to Ol-HDF (Study group) and of the 35 Controls. Table 2 shows the baseline biochemical characteristics of Values are expressed as mean 6 SD or median (range). All P-values are not significant.
Results

Characteristics of the patients
Haemodiafiltration and mineral metabolism in uraemic patients 4033 the same patients. No significant differences were observed for all the variables examined. 4 and PTHint concentrations was evident in the Study group after the switchover from Lf-HD to Ol-HDF (Period 2), while no significant variation in sPO 4 and PTHint concentrations was observed in the Control group during the whole period of observation.
Bone mineral variables changes
The between-groups comparison of pre-dialysis sCa, sPO 4 and PTHint concentrations at baseline, at 6 months and 12 months did not show any significant difference at any time point except for sPO 4 (P < 0.0001) and PTHint (P < 0.01) at 12 months. Figure 1 shows the correlation between the percentage change of pre-dialysis sPO4 and PTHint concentrations in the Study group after the switchover to Ol-HDF. A significant direct correlation was present (r 2 : 0.30; P < 0.01).
At baseline, 12/35 (34%) Controls and 10/30 (33%) Study group patients had concentrations out of the target range (sPO 4 > 5.5 mg/dL). This proportion did not change over time in Controls, while in the Study group, the proportion of patients out of the target range decreased to 3% after the switchover to Ol-HDF (v 2 test: P < 0.001).
Other laboratory tests Table 4 shows the variations over time of haemoglobin (Hb), haematocrit (Hct), sProt, sAlb, Na, K, BW, SBP, DBP, eKt/V and b 2 M concentrations studied either before (Period 1) and after (Period 2) the switchover from Lf-HD to Ol-HDF in the 30 Study group patients (upper panel) and in the 35 Controls treated with Lf-HD (lower panel). Hb, Hct, sProt, sAlb, Na, K, BW, SBP and DBP did not change over time either in Period 1 or Period 2 both in the Study group and in Controls. A significant increase in eKt/V and a significant reduction in b 2 M concentrations were evident after the switchover from Lf-HD to Ol-HDF (Period 2) in the Study group, while no significant variations were seen in the Control group.
Between-groups comparison for each variable evaluated at baseline, at 6 months and 12 months did not show any significant difference at any time point except at 12 months, for eKt/V (P < 0.0001) and b 2 M (P < 0.0001).
Phosphate binders therapy
At the end of Period 1, 24 of the 30 Study group patients (80%) were on phosphate binder treatment. Twenty-two of 24 patients (92%) with sevelamer, 13/24 (54%) with calcium carbonate. At the same time point, the proportion of patients on phosphate binders therapy in Controls was 27/ 35 (77%). Twenty-seven of 27 patients (100%) with sevelamer, 21/27 (77%) with calcium carbonate (v 2 : not significant for all proportions). Figure 2 shows the number of tablets of phosphate binders prescribed at the end of Period 1 and at 12 months. In patients of the Study group, the number of tablets of sevelamer prescribed per day was 4.9 AE 1.6 cp/day and 2.2 AE 0.8 cp/day for calcium carbonate. In Controls, the number of tablets of sevelamer prescribed per day was 4.6 AE 1.4 cp/ day and 2.1 AE 0.8 cp./day for calcium carbonate (P: NS for both sevelamer and calcium carbonate between groups). At 12 months, the number of tablets prescribed to Study group patients remained unchanged, while in Controls, sevelamer prescription increased from 4.6 AE 1.4 cp/day to 5.2 AE 1.4 cp/day (P ¼ 0.001). Calcium carbonate prescription did not change significantly.
Discussion
The main finding from this prospective study is that after 6 months from the switchover from Lf-HD to Ol-HDF, there Table 3 . Variations of pre-dialysis serum calcium, phosphorus and intact parathyroid hormone concentrations studied either before (Period 1) and after (Period 2) the switchover from low flux-haemodialysis to Ol-HDF in the 30 patients in the Study group and in the 35 Controls treated with low flux haemodialysis was a significant reduction in pre-dialysis sPO 4 concentrations, no significant variations in sCa concentrations and a significant reduction of PTHint concentration as compared either to the same group of patients or to the a control group of patients treated only with Lf-HD. This suggests better long-term bone mineral metabolism control by Ol-HDF compared to Lf-HD. During standard haemodialysis, phosphate is primarily removed by diffusion and is therefore dependent upon its plasma concentration. Attempts to improve phosphate clearance by increasing dialyser surface area, changing from low flux to high flux dialysers, increasing blood flow rates or changing dialysate bicarbonate and glucose concentrations have generated conflicting results [16, 17] , so that the failure to adequately clear phosphate during intermittent haemodialysis is now well established. More recent work seems to indicate that adding a convective component to the standard diffusion-based treatment can improve phosphate control, but the results are far from clear [18] [19] [20] . In the present study (Table 3) , sPO 4 and sCa concentrations remained stable during the 6 months of Lf-HD in both the Study group and in Controls, but after the switchover from Lf-HD to post dilutional Ol-HDF, in Study group, there was a significant 24% reduction in predialysis sPO 4 concentrations, while no change occurred in Controls. During the same period of time, sCa concentrations remained remarkably stable in both groups of patients.
Phosphate concentrations can be affected by many factors, dietary intake, age and sex distribution [21] are among them. However, as shown in Table 1 , the Study group and Controls at baseline were well matched for age, sex, dialysis vintage and co-morbidities as well as for other parameters such as haemoglobin, b 2 M, total serum protein, serum albumin plasma sodium and potassium concentrations, body weight, pre-dialysis SBP and DBP and, as a whole, were indicative of a good nutritional status (Table 2) . Moreover (Table 4) , these variables did not change over time in both groups of patients during the entire period of study, thus excluding that each one of these factors could have played any significant role on the variation of sPO 4 concentrations between groups. This was further confirmed by the fact that during Period 1, while performing Lf-HD, sPO 4 concentrations between groups did not differ significantly either at baseline or after 6 months, as well as the proportion of patients with sPO4 out of the target range. In addition, the proportion of patients on phosphate binders therapy and the number of tablets of sevelamer and calcium carbonate prescribed were not different between groups (Figure 1 ). On the contrary, during Period 2, sPO 4 concentrations and the proportion of patients out of target range decreased significantly in patients treated with Ol-HDF (Study group), as compared either to Period 1 or Controls. Phosphate binders therapy remained constant as for protocol in the Study group and showed a slight but significant increase in Controls (Figure 2 ). This sequence of events, and the feature that all the patients were virtually anuric, strongly suggests a direct role of the dialysis modality per se on the significant reduction in sPO 4 concentrations observed in patients switched to Ol-HDF. As a consequence of these variations, a significant decrease in PTHint concentrations was observed in the Study group after the switchover to Ol-HDF, while no significant change in PTHint concentrations was observed in Controls (Table  3 ). This finding was also reinforced by the presence of a significant direct correlation between the magnitude of percentage change of pre-dialysis concentrations of phosphate and PTHint in the Study group after the switch to Ol-HDF ( Figure 1 ). Poor control of serum phosphate and serum calcium has been shown to be an independent factor for all-cause mortality in Stage 5 chronic kidney disease and haemodialysis populations [1] . Phosphate removal during standard HD is primarily dependent on diffusion, and the limiting step to phosphate removal is adequate refilling of the plasma from the intracellular stores [22] . This is the reason why prolonged treatment sessions, such as nocturnal haemodialysis or some forms of continuous dialysis treatments, have been reported to be effective in reducing phosphate concentrations [23, 24] . However, data on the role of increasing the convective component of treatment on phosphate kinetic and removal, particularly in the long run, are still scarce. In previous work, Minutolo et al. [10] have shown, in acute study, that HDF was associated with larger intradialytic removal of phosphate compared to standard HD, and more recently, Penne et al. [25] reported the bone mineral parameters of patients participating in the Convective Transport Study (CONTRAST) showing that the proportion of patients reaching phosphate treatment targets increased significantly in patients treated with HDF, while this was stable in patients treated with standard HD even after adjustment for phosphate binders use. Our results are in agreement with these observations and add further information on the role that convective treatments can exert on mineral metabolism control in dialysis patients. In fact, the addition of~20 litres of convection to the conventional diffusive dialysis treatment was associated with a better dialysis efficiency for both low molecular weight toxins and middle molecular weight toxins. This is evidenced by the 9% increase of Kt/Vurea, showing a slight but significant increase in low molecular weight toxins depuration, mainly cleared by diffusion, but also by the more pronounced 42% significant decrease in plasma b 2 M concentrations, indicating possible better middle molecular weight toxins clearance, mainly cleared by convection (Table 4) . Although at first sight PO4 is a relatively small molecule, it is negatively charged and can exist in plasma water in multiple forms (pyrophosphates, tri-and even decametaphosphates) and also protein bound. As such, these forms of phosphate are much larger than the original molecule, with lower diffusive capabilities and so may be better cleared by the addition of convection. In agreement with the observations by Minutolo et al. [10] , it is probable that increasing convective component of the dialysis treatment in Ol-HDF, by increasing the efficiency of phosphorus removal, could be the reason for the better control of serum phosphate concentrations after the switchover from Lf-HD to Ol-HDF. This finding was highly significant after 6 months from the switch, but extra protocol measurements of pre-dialysis sPO4 concentrations have shown a significant reduction in sPO4 concentrations after 3 months from the switchover (data not shown). This fact, in the presence of stable sCa concentrations and unmodified vitamin D prescription, could be the reason for the slight but significant reduction in PTHint concentrations observed after the switchover from Lf-HD to Ol-HDF, suggesting better control of secondary hyperparathyroidism in patients treated with Ol-HDF as compared to either patients in the Study group during Period 1 or to Controls. This study has some limitations. It is not a randomized study, its generalizability is limited due to the high prevalence of Caucasians (94% in Study group and 92% in Controls) and, although the type and the surface of the membrane were the same, it cannot be excluded that some part of the beneficial effect on sPO4 concentrations in the Study group could be related to the switch to a high-flux membrane. However, since there is no evidence in the literature demonstrating a better control of phosphates during High-flux HD compared to Lf-HD, it is extremely improbable that this could have played a significant role. Since patients in the Study group were also controls themselves, this further reinforces the strength of the observed reduction of sPO 4 concentrations in Ol-HDF. Moreover, no significant differences between Study group and Controls were present in the basal laboratory and clinical characteristics of the patients, thus greatly reducing the possible effect of a selection bias on the results. In conclusion, in this prospective study, the switchover from conventional Lf-HD to Ol-HDF results in a significant reduction of both sPO 4 and PTHint concentrations, no significant changes in sCa concentrations without change in phosphate binders therapy. In Controls, sPO 4 , sCa, and PTHint remained stable over time but at the expense of a small but significant increase of sevelamer intake. This supports the idea that Ol-HDF could be of help in controlling the uraemic mineral metabolism derangement in dialysis patients.
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